Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
123.45
Dollar change
-1.07
Percentage change
-0.86
%
Index- P/E45.70 EPS (ttm)2.70 Insider Own0.00% Shs Outstand3.38B Perf Week1.40%
Market Cap417.68B Forward P/E30.70 EPS next Y4.02 Insider Trans- Shs Float3.38B Perf Month17.34%
Income12.14B PEG16.32 EPS next Q0.78 Inst Own9.14% Short Float0.22% Perf Quarter20.11%
Sales33.70B P/S12.40 EPS this Y23.39% Inst Trans-2.73% Short Ratio1.69 Perf Half Y29.92%
Book/sh4.67 P/B26.45 EPS next Y20.10% ROA29.90% Short Interest7.52M Perf Year73.57%
Cash/sh1.32 P/C93.24 EPS next 5Y2.80% ROE87.44% 52W Range67.66 - 124.86 Perf YTD19.33%
Dividend Est.1.62 (1.32%) P/FCF34.64 EPS past 5Y16.48% ROI64.47% 52W High-1.13% Beta0.42
Dividend TTM2.06 (1.67%) Quick Ratio0.64 Sales past 5Y14.25% Gross Margin84.60% 52W Low82.46% ATR (14)2.55
Dividend Ex-DateAug 18, 2023 Current Ratio0.82 EPS Y/Y TTM56.16% Oper. Margin44.12% RSI (14)66.20 Volatility2.14% 1.79%
Employees63370 Debt/Eq0.25 Sales Y/Y TTM34.77% Profit Margin36.04% Recom2.03 Target Price118.54
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q71.63% Payout36.04% Rel Volume0.80 Prev Close124.52
Sales Surprise4.87% EPS Surprise6.77% Sales Q/Q44.01% EarningsJan 31 BMO Avg Volume4.44M Price123.45
SMA205.22% SMA5013.21% SMA20030.57% Trades Volume3,555,595 Change-0.86%
Date Action Analyst Rating Change Price Target Change
Jan-23-24Initiated Morgan Stanley Overweight $120
Jan-16-24Resumed UBS Neutral
Dec-01-23Initiated Cantor Fitzgerald Overweight $120
Oct-02-23Initiated Argus Buy $110
Jul-14-23Initiated HSBC Securities Buy
Jul-15-22Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22Downgrade UBS Neutral → Sell
Jun-27-22Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22Upgrade JP Morgan Neutral → Overweight
May-31-22Upgrade Guggenheim Neutral → Buy
Today 07:10AM
Feb-23-24 12:44PM
08:33AM
Feb-22-24 09:21AM
07:00AM
01:00AM Loading…
01:00AM
Feb-21-24 10:00AM
09:45AM
09:03AM
Feb-20-24 01:58PM
06:55AM
Feb-19-24 09:29AM
Feb-18-24 09:30AM
Feb-17-24 01:29PM
Feb-16-24 01:35PM
01:27PM Loading…
01:27PM
Feb-15-24 11:35AM
11:05AM
Feb-14-24 04:43PM
11:48AM
10:23AM
08:30AM
06:59AM
02:59AM
Feb-13-24 05:50AM
Feb-12-24 11:22AM
09:30AM
09:15AM
07:13AM
05:06AM
05:03AM Loading…
05:03AM
12:50AM
12:47AM
Feb-11-24 01:06PM
12:25PM
10:15AM
Feb-10-24 11:40AM
09:53AM
08:30AM
06:49AM
01:47AM
Feb-09-24 10:47AM
10:17AM
09:13AM
08:14AM
Feb-08-24 04:56PM
10:00AM
09:55AM
08:23AM
06:48AM
06:37AM
06:15AM
04:53AM
Feb-07-24 03:22PM
12:55PM
12:23PM
11:53AM
06:53AM
Feb-06-24 05:23PM
04:37PM
02:48PM
01:43PM
10:25AM
08:37AM
02:49AM
02:20AM
Feb-05-24 06:25PM
06:07PM
04:35PM
02:03PM
01:46PM
01:21PM
12:31PM
12:27PM
10:57AM
10:35AM
10:29AM
10:26AM
10:01AM
08:10AM
07:40AM
06:47AM
06:41AM
06:18AM
06:16AM
06:04AM
02:59AM
Feb-04-24 07:10AM
04:05AM
Feb-02-24 03:30PM
12:45PM
05:03AM
Feb-01-24 02:51PM
02:10PM
11:29AM
10:36AM
06:33AM
Jan-31-24 07:20PM
06:16PM
04:31PM
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.